Adelaide, Australia | North Carolina, USA – Avance Clinical, the award-winning Australian and North American market-leading CRO for biotechs, will attend World Vaccine Congress in Washington DC (April 1-4, 2024) and share the latest clinical trial client news including the Uvax Bio announcement. (Booth #267) Avance Clinical CEO, Yvonne Lungershausen said the World Vaccine Congress was an… Source ..read more

New Biotech Report by Frost & Sullivan Adelaide, Australia | San Francisco, USA – Avance Clinical, the award-winning Australian and North American market-leading CRO for biotechs, has today spoken with SCRIP Intelligence about their positive outlook for the US biotech sector following the J.P. Morgan Healthcare Conference and Biotech Showcase meetings. (read the full article here)… Source ..read more

February 20, 2024 Avance Clinical and Ryght Partner to Bring Novel GenAI Technologies to Clinical Research Networks Revolutionizing Clinical Research: Accelerate Innovation with GenAI by Ryght & Avance Clinical Laguna Beach, California – [February 20, 2024] – Ryght, an innovator in generative artificial intelligence (GenAI) technology for the Life Science industry… Source ..read more

This extensive analysis of the biotech landscape has identified the key challenges and solutions for biotechs seeking the right CRO partner to progress their drug development programs. The report noted that biotechs are increasingly wanting to partner with mid-sized, agile, and responsive CROs with a proven ability to rapidly advance quality clinical programs. It found there is a perception among... Source ..read more

Adelaide, Australia | North Carolina, USA – Avance Clinical, the Australian and North American market-leading CRO for biotechs, has signed a strategic technology MOU with leading Korean decentralized clinical trials (DCTs) and eClinical technology company JNPMEDI Inc. The agreement expands Avance Clinical’s capabilities in the Asia-Pacific biotech clinical trials sector. Anne Sim... Source ..read more

Join us for an informative webinar as we delve into the world of psychedelic trials and the evolving regulatory landscape surrounding these transformative therapies. Explore the promising efficacy of psychedelics like psilocybin, MDMA, 5-methoxy-dimethyltryptamine, and ibogaine in treating conditions such as depression, PTSD, anxiety, and substance use disorder. During this webinar, we will: Our... Source ..read more

Adelaide, Australia | North Carolina, USA – Avance Clinical, the award-winning Australian and North American market leading CRO for biotechs, has again been recognised for its contribution to International Health in the 61st Australian Export Awards 2023. The Australian Export Awards ceremony will be held on 30 November in Canberra at Parliament House. CEO Yvonne Lungershausen said... Source ..read more

Dt & SanoMedics Chairman, Charles Park (Park, Chae Gyoo) and Avance Clinical CEO Yvonne Lungershausen co-hosting the Global Clinical Trial Strategy Symposium in Korea last week. Adelaide, Australia | North Carolina, USA – Avance Clinical, the Australian and North American market-leading CRO for biotechs, was asked to present their GlobalReady drug development solution to more than 45 Korean... Source ..read more

Adelaide, Australia | North Carolina, USA – Avance Clinical, the award-winning Australian and North American market-leading CRO for biotechs, is proud to announce its gold sponsorship of California Life Sciences (CLS) Innovation and Entrepreneurship programming. Liahna Toy, Vice President, Commercial Business Development at Avance Clinical, said the sponsorship was an ideal way of supporting early... Source ..read more

Adelaide, Australia | Raleigh, North Carolina, USA – Avance Clinical, the award-winning Australian and North American market-leading CRO for biotechs, announces two key appointments in the US to support its continued global growth. Kevin Leach joins as Senior Vice President of Scientific and Regulatory Affairs, based in Massachusetts, USA. Kevin has a background in the biopharma industry with... Source ..read more